SubjectsSubjects(version: 945)
Course, academic year 2023/2024
   Login via CAS
Pharmacoeconomics and Health Technology Assessment - GAF287
Title: Pharmacoeconomics and Health Technology Assessment
Guaranteed by: Department of Social and Clinical Pharmacy (16-16220)
Faculty: Faculty of Pharmacy in Hradec Králové
Actual: from 2022
Semester: winter
Points: 0
E-Credits: 2
Examination process: winter s.:
Hours per week, examination: winter s.:0/14, Ex [HS]
Capacity: unknown / unlimited (unknown)
Min. number of students: 5
4EU+: no
Virtual mobility / capacity: no
Key competences:  
State of the course: taught
Language: English
Teaching methods: full-time
Teaching methods: full-time
Level:  
Note: course can be enrolled in outside the study plan
enabled for web enrollment
Guarantor: PharmDr. Jiří Klimeš, Ph.D.
Annotation -
Last update: PharmDr. Jiří Klimeš, Ph.D. (29.09.2022)
The aim is to make students familiar with the complex evaluation of health interventions (technologies), namely drugs, concerning their relative/comparative efficacy, safety and cost-effectiveness. These aspects are integrated within HTA (Health Technology Assessment), which represents an important objective tool for fair and balanced definition and understanding of the added value of drugs (and health technologies in general). In developed countries across the globe, HTA systems are commonly applied as a part of regulatory and decision-making processes, including pricing and reimbursement of health technologies and/or their inclusion and positioning in national formularies, guidelines, or therapeutic standards. In the Czech Republic and other European countries the environment in terms of HTA development is under cultivation. The demand for knowledge and methods in this healthcare areas has been growing both at the site of public authorities (e.g. ministry of health, drug agency), 3rd party payers i.e. insurance funds, healthcare providers and healthcare (pharmaceutical, medical devices) industry. The topics presented and discussed will focus on current HTA practices and they also follow-up on particular chapters taught in social pharmacy subject.
Course completion requirements
Last update: PharmDr. Jiří Klimeš, Ph.D. (29.09.2022)

Credit = team (2 – 3 students) work presentation

Literature
Last update: PharmDr. Jiří Klimeš, Ph.D. (29.09.2022)

Recommended:

Syllabus
Last update: PharmDr. Jiří Klimeš, Ph.D. (29.09.2022)

·         Funding and organization of health care, focus on pharmaceuticals

·         HTA (Health Technology Assessment) characteristics, definition

·         Health economics and pharmacoeconomics

·         Regulatory processes: marketing authorization vs. reimbursement and patient access

·         Clinical evidence interpretation (clinical studies, meta-analyses, indirect comparisons)

·         Evidence hierarchy, sources of evidence-base medicine

·         Range of clinical outcomes: from surrogates to QALY (Quality-Adjusted Life-Year) 

·         Pharmacoeconomic modelling: reasons, approaches, methods

·         Integrations of various evidence types (clinical, economic) in complex HTA report

·         In practice lessons the abovementioned topics are discussed and exercised using real-world model examples in pharmacotherapy of osteoporosis and diabetes.

Teaching methods
Last update: PharmDr. Jiří Klimeš, Ph.D. (29.09.2022)

Interactive seminar

 

Requirements to the exam
Last update: PharmDr. Jiří Klimeš, Ph.D. (29.09.2022)

Conditions for successful completion of the course:

·         Credit: 100% participation in seminars

·         Exam: group project + colloquium

 

Tompics for the final colloquium:

·         Financing and organization of health care taking into account pharmacotherapy

·         Characteristics of HTA (health technology assessment), partial aspects

·         basic concepts from health economics and pharmacoeconomics

·         Basic types of HE analysis

·         regulatory processes: registration vs. determining the reimbursement of medicines

·         basic concepts of evidence-based medicine and interpretation of medical evidence (clinical studies, meta-analyses, indirect comparisons)

·         sources of expert information on medicines

·         hierarchy of expert evidence

·         different types of clinical outcomes, surrogate markers, QALY

·         pharmacoeconomic modeling, reasons, practical procedures

·         integration of clinical, economic and other aspects in a comprehensive HTA report

 
Charles University | Information system of Charles University | http://www.cuni.cz/UKEN-329.html